EUCTR2009-011884-35-HU进行中（未招募）不适用
Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A randomized multicenter phase II trial.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 106
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histologically, cytologically or radiologically confirmed diagnosis of HCC, localized but surgically unresectable or metastatic.
- •HCC stage B or C according to the Barcelona Clinic Liver Cancer (BCLC) staging classification.
- •Child-Pugh class A or mildly decompensated Child-Pugh class B liver dysfunction.
- •Measurable disease: spiral/multi-slice CT/MRI according to revised RECIST 1.1.
- •WHO performance status 0-1.
- •Adequate hematological values: hemoglobin = 90 g/L, neutrophils = 1.5 x 109/L, platelets = 75 x 109/L.
- •Adequate renal function: creatinine clearance = 40 mL/min.
- •Adequate hepatic function: ALT = 5 x upper limit of normal (ULN).
- •Adequate coagulation parameter: INR = 2.
- •Urine dipstick for proteinuria = 1+ or protein in spot urine sample < 0.6 g/L.
- •Age = 18 years.
- •Women are not breastfeeding, are using effective contraception if sexually active, are not pregnant and agree not to become pregnant during participation in the trial and during the 12 months thereafter. A negative pregnancy test is mandatory for all women < 50 years (unless considered unnecessary by the investigator). Men agree not to father a child during participation in the trial and during the 12 months thereafter.
- •Patient compliance and geographic proximity allow proper staging and follow-up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior systemic anti-cancer treatment for HCC.
- •Treatment with estrogen containing supplementary therapy.
- •Previous malignancy within 5 years with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.
- •Prior organ transplantation.
- •Patients with locally advanced disease who are candidates for radical surgery.
- •Known fibrolamellar HCC or mixed cholangiocarcinoma/HCC.
- •History of hemorrhagic or thrombotic cerebrovascular event in the past 12 months.
- •Documented variceal hemorrhage within 3 months before randomization.
- •Requirement of anticoagulant therapy except for low-dose anticoagulants for maintenance of patency of central venous access or prevention of deep vein thrombosis (DVT).
- •History (within last six months) or presence of clinically significant acute or unstable cardiovascular, cerebrovascular, renal, gastrointestinal, pulmonary, endocrine, central nervous system or immunological disorders (with the exception of the presence of hepatitis B virus (HBV), HCV hepatitis, or cirrhosis).
- •Clinical symptoms or history of CNS metastases or leptomeningeal disease (no imaging required).
- •Encephalopathy.
- •Known HIV infection.
- •Active infection requiring i.v. antibiotics at randomization.
- •Arterial hypertension = 150/100 mmHg despite therapy.
- •Ongoing cardiac dysrhythmias of NCI CTCAE grade = 2, or atrial fibrillation of any grade, prolongation of QTc > 500 msec in screening electrocardiogram (ECG) or history of familial long QT syndrome.
- •Repeated paracentesis (more than 1 per month).
- •Concurrent treatment with other experimental drugs or other anti-cancer therapy, treatment in a clinical trial within 30 days prior to randomization.
- •Chronic treatment with systemic steroids or another immunosuppressive agent.
- •Current use or anticipated need for drugs that are known CYP3A4 inhibitors or inducers (for a comprehensive list see http://medicine.iupui.edu/clinpharm/ddis/), unless the drugs are medically necessary and no substitutes are available.
- •Inability to take oral medications.
- •Psychiatric disorder precluding understanding of information of trial-related topics, giving informed consent or interfering with compliance for oral drug intake
研究者
相似试验
进行中（未招募）
1 期
Behandlung mit Sorafenib oder mit Sorafenib und Everolimus bei Patienten mit fortgeschrittenem Leberzellkrebs.Patients with unresectable hepatocellular carcinoma.MedDRA version: 14.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864EUCTR2009-011884-35-ATSwiss Group for Clinical Cancer Research106
已完成
2 期
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver CancerLiver CancerNCT01005199Swiss Group for Clinical Cancer Research106
进行中（未招募）
1 期
Combination of Erlotonib plus Sorafenib in Patients with unresectable Hepatocellular Carcinoma; a randomized placebo controlled Phase II pilot trial. - Erlosora-1nresectable Hepatocellular CarcinomaEUCTR2008-001401-42-ATMedizinische Universität Wien, Univ. KlM III, Klinische Abt. f. Gastroenterologie/Hepatologie90
已完成
1 期
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine HydrochlorideAcinar Cell Adenocarcinoma of the PancreasDuct Cell Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage IV Pancreatic CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00981162Roswell Park Cancer Institute12
进行中（未招募）
1 期
Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma - SORAMICCarcinoma hepatocelular (CHC)Patients with Hepatocellular carcinoma (liver-predominant disease)MedDRA version: 12.1Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableMedDRA version: 12.1Level: LLTClassification code 10019829Term: Hepatocellular carcinoma recurrentMedDRA version: 12.1Level: LLTClassification code 10019830Term: Hepatocellular carcinoma resectableMedDRA version: 12.1Level: LLTClassification code 10049010Term: Carcinoma hepatocellularEUCTR2009-012576-27-SIMedical Faculty, University Magdeburg665